Neurogene Inc. Increase Decrease In Operating Lease Liability
Neurogene Inc. (NGNE) reported Increase Decrease In Operating Lease Liability of -$1.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Neurogene Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$780.00K.
- Neurogene Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$755.00K.
- Neurogene Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$740.00K.
- Neurogene Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$745.00K.
- Neurogene Inc. increase decrease in operating lease liability for fiscal 2025 was -$2.92M.
- Neurogene Inc. increase decrease in operating lease liability for fiscal 2024 was -$2.57M.
- Neurogene Inc. increase decrease in operating lease liability for fiscal 2023 was -$678.00K.
- Neurogene Inc. increase decrease in operating lease liability for fiscal 2022 was -$610.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 3 month as first filed | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 6 month as first filed | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$780.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.53M 10-Q · filed 2026-08-11 | -$2.27M derived: sum of 3 quarters · filed 2026-08-11 | -$3.02M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$755.00K 10-Q · filed 2026-05-12 | -$1.50M derived: sum of 2 quarters · filed 2026-05-12 | -$2.24M derived: sum of 3 quarters · filed 2026-05-12 | -$2.97M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$740.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$1.49M derived: sum of 2 quarters · filed 2026-03-24 | -$2.21M derived: sum of 3 quarters · filed 2026-08-11 | -$2.92M 10-K · filed 2026-03-24 | ||||
| 2025-09-30 | -$745.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.47M derived: sum of 2 quarters · filed 2026-08-11 | -$2.18M 10-Q · filed 2025-11-13 | -$2.86M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$727.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.43M 10-Q · filed 2026-08-11 | -$2.11M derived: sum of 3 quarters · filed 2026-08-11 | -$2.77M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$706.00K 10-Q · filed 2026-05-12 | -$1.38M derived: sum of 2 quarters · filed 2026-05-12 | -$2.04M derived: sum of 3 quarters · filed 2026-05-12 | -$2.67M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | -$678.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$1.33M derived: sum of 2 quarters · filed 2026-03-24 | -$1.96M derived: sum of 3 quarters · filed 2026-03-24 | -$2.57M 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | -$654.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.29M derived: sum of 2 quarters · filed 2025-11-13 | -$1.90M 10-Q · filed 2025-11-13 | -$2.07M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$632.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.24M 10-Q · filed 2025-08-11 | -$1.42M derived: sum of 3 quarters · filed 2025-08-11 | -$1.59M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | -$609.00K 10-Q · filed 2025-05-09 | -$786.00K derived: sum of 2 quarters · filed 2025-05-09 | -$956.00K derived: sum of 3 quarters · filed 2025-05-09 | -$1.12M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | -$177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$347.00K derived: sum of 2 quarters · filed 2025-03-24 | -$514.00K derived: sum of 3 quarters · filed 2025-03-24 | -$678.00K 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | -$170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | -$337.00K derived: sum of 2 quarters · filed 2024-11-18 | -$501.00K 10-Q · filed 2024-11-18 | -$1.01M 10-Q · filed 2023-11-14 | -$252.00K derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2023-06-30 | -$167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$331.00K 10-Q · filed 2024-08-09 | -$664.00K 10-Q · filed 2023-08-10 | -$82.00K derived: sum of 3 quarters · filed 2024-08-09 | -$378.00K derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | -$164.00K 10-Q · filed 2024-05-10 | -$326.00K 10-Q · filed 2023-05-08 | $85.00K derived: sum of 2 quarters · filed 2024-05-10 | -$211.00K derived: sum of 3 quarters · filed 2024-05-10 | -$499.00K derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$47.00K derived: sum of 2 quarters · filed 2024-03-18 | -$335.00K derived: sum of 3 quarters · filed 2024-03-18 | -$610.00K 10-K · filed 2024-03-18 | -$1.17M 10-K · filed 2023-03-20 | |||
| 2022-09-30 | -$296.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$584.00K derived: sum of 2 quarters · filed 2023-11-14 | -$859.00K 10-Q · filed 2023-11-14 | -$1.12M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$288.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$563.00K 10-Q · filed 2023-08-10 | -$823.00K derived: sum of 3 quarters · filed 2023-08-10 | -$1.07M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$275.00K 10-Q · filed 2023-05-08 | -$535.00K derived: sum of 2 quarters · filed 2023-05-08 | -$786.00K derived: sum of 3 quarters · filed 2023-05-08 | -$1.07M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | -$260.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$511.00K derived: sum of 2 quarters · filed 2023-03-20 | -$791.00K derived: sum of 3 quarters · filed 2023-03-20 | -$687.00K 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$251.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$531.00K derived: sum of 2 quarters · filed 2022-11-14 | -$427.00K 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$176.00K 10-Q · filed 2022-08-09 | ||||||
| 2021-03-31 | $104.00K 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $598.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |